MET - MET proto-oncogene, receptor tyrosine kinase Gene

Species: Sus scrofa

Gene Type: protein coding
Gene ID: 654328

About MET

Primary_assembly 18: 29,426,048-29,541,512 reverse strand.Sscrofa11.1:CM000829.5

This gene has 4 transcripts (splice variants), 207 orthologues and 52 paralogues. Broad expression in kidney (RPKM 13.), lung (RPKM 9.6) and 7 other tissues.

MET Products (1)

mRNA Protein Name
NM_001038008.1 NP_001033097.1 hepatocyte growth factor receptor precursor

MET Protein Structure

Sema

Sema: cl15693 (24 - 515)

PSI

PSI: smart00423 (518 - 560)

IPT_plexin_repeat1

IPT_plexin_repeat1: cd01180 (562 - 655)

IPT

IPT: cl15674 (656 - 739)

IPT

IPT: cl15674 (741 - 836)

IPT_PCSR

IPT_PCSR: cd00603 (838 - 931)

PTKc_Met_Ron

PTKc_Met_Ron: cd05058 (1081 - 1342)

  • 0
  • 300
  • 600
  • 900
  • 1200
  • 1381 a.a.
Protein Preferred Names Protein Names

hepatocyte growth factor receptor

  • HGF receptor

  • HGF/SF receptor

  • SF receptor

  • met proto-oncogene (hepatocyte growth factor receptor)

  • met proto-oncogene tyrosine kinase

  • proto-oncogene c-Met

  • scatter factor receptor

  • tyrosine-protein kinase Met

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13016 Cabozantinib Inhibitor 99.97% Yes
HY-13404 Capmatinib Inhibitor 99.71% Yes
HY-14721 Tepotinib Inhibitor 99.94% Yes

Clinical Phase

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-16446 SAR125844 Inhibitor 98.17% Phase 2
HY-12035 AMG-208 Inhibitor 99.86% Phase 2
HY-50683 JNJ-38877605 Inhibitor 99.95% Phase 1
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99455 Bafisontamab Inhibitor 99.9% Phase 3

Pre-clinical Phase

Bioactive Molecules (23)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-123961 SJF-8240 Degrader 99.33% Unkown
HY-168135 PROTAC c-Met degrader-1 Degrader 98.48% Unkown
HY-114357A DS-1205b free base Inhibitor 99.92% Unkown
HY-157551 JNK-IN-16 Inhibitor 99.82% Unkown
HY-183579 c-Met-IN-27 Inhibitor / Unkown
HY-171824 PROTAC c-Met Degrader-4 Degrader / Unkown
HY-162803 c-Met-IN-24 Inhibitor / Unkown
HY-45124 3-Fluoro-desmethyl-cabozantinib / Unkown
HY-178348 PARP1/c-Met-IN-2 Inhibitor / Unkown
HY-181776 c-Met-IN-31 Inhibitor / Unkown
HY-179098 Multi-target kinase-IN-8 Inhibitor / Unkown
HY-177134 Taligantinib Inhibitor / Unkown
HY-161372 PARP1/c-Met-IN-1 Inhibitor / Unkown
HY-181928 PARP1/c-Met-IN-3 Inhibitor / Unkown
HY-184305 c-Met-IN-30 Inhibitor / Unkown
HY-123237 KRC-108 Inhibitor / Unkown
HY-120908 c-Met-IN-16 Inhibitor / Unkown
HY-D3352 EMI-137 / Unkown
HY-175321 PROTAC c-Met degrader-6 Degrader / Unkown
HY-175848 NSC 850745 Inhibitor / Unkown
HY-149675 VEGFR-2/c-Met-IN-2 Inhibitor / Unkown
HY-157387 c-Met-IN-22 Inhibitor / Unkown
HY-179034 CAIX/XII-IN-16 Inhibitor / Unkown
Bioactive MoleculesInhibitory Antibodies (2)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P992481 VERT-002 Degrader / Unkown
HY-P991565 CE-355621 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens MET NCBI NCBI:4233